Clinical Scorecard: Machine Learning Uncovers TIME Subtypes Correlating EGFR Mutations with Immune Profiles in Lung Adenocarcinoma
At a Glance
Category
Detail
Condition
Lung adenocarcinoma (LUAD) with EGFR mutations
Key Mechanisms
EGFR mutations shape tumor immune microenvironment (TIME) by enriching immunosuppressive cells and reducing cytotoxic immune populations
Target Population
Patients with EGFR-mutant and wild-type lung adenocarcinoma
Care Setting
Oncology and precision immunotherapy clinical settings
Key Highlights
EGFR-mutant LUAD tumors show enrichment of TIGIT+ regulatory T cells, neutrophils, and macrophages indicating an immunosuppressive TIME.
Wild-type LUAD tumors contain abundant ZNF683+ CD8+ tissue-resident memory T cells, diverse memory B cells, and FGFBP2+ CD16high natural killer cells reflecting an immune-active TIME.
Machine learning using non-negative matrix factorization identified five TIME subtypes with EGFR-mutant patients clustering into immunosuppressive profiles linked to poor prognosis.
Guideline-Based Recommendations
Diagnosis
Utilize single-cell transcriptomic profiling to characterize tumor immune microenvironment heterogeneity in LUAD.
Assess EGFR mutation status to inform immune microenvironment classification and prognosis.
Management
Consider EGFR mutation status when selecting immunotherapy strategies due to differential immune cell infiltration and checkpoint expression.
Explore immunotherapies targeting immunosuppressive cells (e.g., TIGIT+ regulatory T cells) in EGFR-mutant LUAD.
Leverage PD-1 blockade therapies enhanced by FGFBP2+ natural killer cells in immune-active TIME subtypes.
Monitoring & Follow-up
Monitor immune cell composition changes, especially regulatory T cells and cytotoxic lymphocytes, to evaluate treatment response.
Track emergence of immunosuppressive TIME subtypes associated with EGFR mutations for prognosis.
Risks
EGFR-mutant LUAD patients exhibit lower response rates to immune checkpoint inhibitors due to immunosuppressive TIME.
Acquired resistance to EGFR tyrosine kinase inhibitors typically develops after ~1 year, complicating treatment.
Patient & Prescribing Data
Lung adenocarcinoma patients stratified by EGFR mutation status
EGFR-mutant patients show poor response to immune checkpoint inhibitors; immunotherapy efficacy varies with TIME subtype; FGFBP2+ NK cells may enhance PD-1 blockade efficacy.
Clinical Best Practices
Incorporate machine learning-based single-cell transcriptomic analysis for precise immunogenomic profiling in LUAD.
Stratify patients by EGFR mutation and TIME subtype to guide personalized immunotherapy decisions.
Target immunosuppressive cell populations in EGFR-mutant LUAD to improve immunotherapy outcomes.
Use flow cytometry and preclinical models to validate immune cell functions and therapeutic targets.
